News | Deal AnnouncementSVB Securities Serves as Placement Agent for Morphimmune’s $125 Million Private PlacementJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Axsome Therapeutics’ (Nasdaq: AXSM) $225 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for MoonLake Immunotherapeutics’ (Nasdaq: MLTX) $400 Million Upsized Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor for Talaris Therapeutics’ (Nasdaq: TALS) Proposed Merger with Tourmaline BioJune 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Zentalis Pharmaceuticals’ (Nasdaq: ZNTL) $250 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to Upperline Health on its $58 Million Strategic Capital Investment from Crestline InvestorsJune 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Kura Oncology’s (Nasdaq: KURA) $100 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Disc Medicine’s (Nasdaq: IRON) $137.2 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Elevation Oncology’s (Nasdaq: ELEV) $50 Million Follow-On OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for NewAmsterdam Pharma’s (Nasdaq: NAMS) $159 Million Secondary OfferingJune 2023
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Transaction Data Systems, Inc. on its Merger with Outcomes™, a Cardinal Health BusinessJune 2023
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for HOOKIPA Pharma’s (Nasdaq: HOOK) $50 Million Follow-On OfferingJune 2023